IP Library Granted Patent US 7,666,624
Granted Patent B2
US 7,666,624 · App. 11/880,195 · Granted Feb 23, 2010

Modified plant viruses and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,666,624
App. No.
11/880,195
Granted
Feb 23, 2010
Kind
B2
Abstract

The present invention relates to modulating the nature and/or level of an immune response to a molecule. In particular, the invention relates to effecting an increase in the TH1 immune response to molecules such as, but not limited to, antigens or immunogens. The invention also relates to reducing a TH2 immune response to molecules. More particularly, the invention relates to altering the level of TH1- and TH2-associated immunoglobulins, the level of proliferation of TH1- and TH2-associated cytokines, and the level of proliferation of TH1 and TH2 cells.

Claims (23)

1. A process for producing a virus-like particle comprising:

providing a plant virus expressing a heterologous peptide on an exposed portion of a coat protein of said plant virus, which is capable of conjugating to a peptide of interest, wherein said plant virus is a cowpea mosaic virus (CPMV), and wherein said heterologous peptide comprises one or more acidic amino acids and an equal number of basic amino acids; and

conjugating said peptide of interest to said heterologous peptide to generate a conjugate.

2. The process of claim 1 , wherein conjugating said peptide of interest comprises chemically conjugating said peptide of interest.

3. The process of claim 1 , wherein said peptide of interest is an antigen of a source selected from the group consisting of an animal pathogen and a cancer cell.

4. The process of claim 1 , wherein said acidic amino acids are selected from aspartic acid, glutamic acid, and cysteine, and said basic amino acids are selected from lysine, arginine, and histidine.

5. The process of claim 1 , wherein said heterologous peptide comprises a sequence of contiguous charged amino acids selected from a first sequence consisting of contiguous acidic amino acids and a second sequence consisting of contiguous basic amino acids.

6. The process of claim 5 , wherein said sequence of contiguous charged amino acids occurs in said heterologous peptide as a repeating sequence.

7. The process of claim 5 , wherein said heterologous peptide comprises said first and second sequences, and wherein said first sequence is contiguous with said second sequence.

8. The process of claim 7 , wherein said contiguous first and second sequences occur in said heterologous peptide as a repeating sequence.

9. The process of claim 1 , wherein said heterologous peptide comprises Asp-Glu-Gly-Lys-Gly-Lys-Gly-Lys-Gly-Lys-Asp-Glu listed as SEQ ID NO :29.

10. The process of claim 1 , wherein said conjugate is immunogenic.

11. A process for producing a virus-like particle comprising:

providing a plant virus containing a polynucleotide encoding a heterologous peptide that is expressed on an exposed portion of a coat protein of said plant virus, said heterologous peptide being capable of conjugating to a peptide of interest, wherein said plant virus is a comovirus, and wherein said heterologous peptide comprises one or more acidic amino acids and an equal number of basic amino acids;

infecting a host cell with said plant virus; and

allowing replication and expression of said polynucleotide in the host cell.

12. The process of claim 11 , wherein said acidic amino acids are selected from aspartic acid, glutamic acid, and cysteine, and said basic amino acids are selected from lysine, arginine, and histidine.

13. The process of claim 11 , wherein said heterologous peptide comprises a sequence of contiguous charged amino acids selected from a first sequence consisting of contiguous acidic amino acids and a second sequence consisting of contiguous basic amino acids.

14. The process of claim 13 , wherein said sequence of continuous charged amino acids occurs in said heterologous peptide as a repeating sequence.

15. The process of claim 13 , wherein said heterologous peptide comprises said first and second sequences, and wherein said first sequence is contiguous with said second sequence.

16. The process of claim 15 , wherein said contiguous first and second sequences occur in said heterologous peptide as a repeating sequence.

17. The process of claim 11 , wherein said heterologous peptide comprises Asp-Glu-Gly-Lys-Gly-Lys-Gly-Lys-Gly-Lys-Asp-Glu listed as SEQ ID NO:29.

18. The process of claim 11 , wherein said plant virus is a cowpea mosaic virus (CPMV).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2023
From: BRENNAN, FRANK
To: THE DOW CHEMICAL COMPANY
Reel/Frame 062376/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2010
From: DOW GLOBAL TECHNOLOGIES, INC.; THE DOW CHEMICAL COMPANY
To: PFENEX, INC.
Reel/Frame 023922/0301 →